AhR agonist effects on NEP in APP/PS1 mice

Validation Score: 0.900 Price: $0.50 Alzheimer's disease APP/PS1 mice Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting NEP in APP/PS1 mice. Primary outcome: NEP expression and enzyme activity

Description

In vivo study using APP/PS1 transgenic mice to investigate the effects of AhR agonists on NEP expression and enzyme activity. The experiment tested the same AhR ligands used in the cell culture studies (L-Kynurenine, FICZ, diosmin, and indole-3-carbinol) in a well-established mouse model of Alzheimer's disease. This study aimed to validate the cellular findings in a more physiologically relevant system and determine if AhR activation could have therapeutic potential for Alzheimer's disease through enhanced Aβ clearance mechanisms.

TARGET GENE

NEP

MODEL SYSTEM

APP/PS1 mice

ESTIMATED COST

TIMELINE

0 months

PATHWAY

AhR signaling pathway

SOURCE

extracted_from_pmid_34522212

PRIMARY OUTCOME

NEP expression and enzyme activity

Scoring Dimensions

📖 Wiki Pages

APP Gene Dosage Reduction Therapy for Down Syndromidea APP/PS1 Dual Transgenic Mouse Modelmodel APP-Overexpressing Neuronscell APP — Amyloid Precursor Proteingene APP-BACE1-Fe65 Complexmechanism APP/PS1 Double Transgenic Mouse Modelmechanism APP Dutch Mutation (APP Dutch)disease APP Flemish Mutation (APP Flemish)disease APP Genegene APP Swedish Mutation (APPswe)mutation APP→Amyloid-beta→Plaque→Alzheimer's Disease Causalpathway APP Amyloid Pathway in Alzheimer's Diseasemechanism APP Arctic Mutation (APP Arctic)disease APP Processing and Amyloid-Beta Productionmechanism APP Proteinprotein

Protocol

Establish APP/PS1 mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for NEP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure NEP expression and enzyme activity together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5.

...

Expected Outcomes

The intervention targeting NEP shifts NEP expression and enzyme activity in the predicted direction relative to the matched control arm.

Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.

The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.

Success Criteria

Prespecified primary endpoint (NEP expression and enzyme activity) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

Related Hypotheses (5)

TREM2-mediated microglial tau clearance enhancement0.618

LRP1-Dependent Tau Uptake Disruption0.600

VCP-Mediated Autophagy Enhancement0.595

Extracellular Vesicle Biogenesis Modulation0.582

HSP90-Tau Disaggregation Complex Enhancement0.575

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.